Navigation Links
Non-inherited mutations account for many heart defects, Yale researchers find
Date:5/12/2013

New mutations that are absent in parents but appear in their offspring account for at least 10% of severe congenital heart disease, reveals a massive genomics study led, in part, by researchers at the Yale School of Medicine.

The analysis of all the genes of more than 1800 individuals found hundreds of mutations that can cause congenital heart disease, the most common form of birth defect that afflicts nearly 1% of all newborns. In particular, the study found frequent mutations in genes that modify histones, proteins that package DNA in the nucleus and orchestrate the timing and activation of genes crucial to development of the fetus. The results of the study, part of the Pediatric Cardiac Genomics Consortium funded by the NIH's National Heart, Lung, and Blood Institute (NHLBI), were published online May 12 in the journal Nature.

"These findings provide new insight into the causes of this common congenital disease," said Richard Lifton, Sterling Professor and chair of the Department of Genetics, investigator for the Howard Hughes Medical Institute, and a senior author of the paper. "Most interestingly, the set of genes mutated in congenital heart disease unexpectedly overlapped with genes and pathways mutated in autism. These findings suggest there may be common pathways that underlie a wide range of common congenital diseases."

"This is an important piece of the puzzle that gives us a clearer picture of the causes of congenital heart disease," said Gary H. Gibbons, M.D., director of the NHLBI. "What this international, multi-center collaborative research effort was able to accomplish, in a small amount of time, is truly remarkable. The state-of-the-art sequencing techniques that were used are allowing us to push the envelope and envision a day when we may be able to better treat and eventually prevent congenital heart disease in the early stages of heart formation."

The mutations can occur at the same site, and both increase a
'/>"/>

Contact: Bill Hathaway
william.hathaway@yale.edu
203-432-1322
Yale University
Source:Eurekalert

Page: 1 2

Related biology news :

1. BRG1 mutations confer resistance to hormones in lung cancer
2. Gene mutations cause massive brain asymmetry
3. Interacting mutations promote diversity
4. Mutations in autism susceptibility gene increase risk in boys
5. UMMS researchers isolate gene mutations in patients with inherited amyotrophic lateral sclerosis
6. New gene mutations linked to ALS and nerve cell growth dysfunction
7. Key mutations discovered for most common childhood brain cancer
8. BGI reports the latest finding on NMNAT1 mutations linked to Leber congenital amaurosis
9. Gene mutations linked to most cases of rare disorder -- Alternating Hemoplegia of Childhood
10. New method provides fast, accurate, low cost analysis of BRCA gene mutations in breast cancer
11. Populations survive despite many deleterious mutations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2015)... Calif. , July 13, 2015 ... developer of human interface solutions, today announced sampling ... touch and display driver integration (TDDI) product targeting ... the first to combine Synaptics , best-in-class ... proven display driver technology developed in the company,s ...
(Date:7/9/2015)... July 07, 2015 ... addition of the "Biometrics for Banking; Market ... report to their offering. The ... to this growth and the forecast is that ... revenue for companies involved in delivering biometric systems ...
(Date:7/8/2015)... 2015 Summary Pancreatic cancer is the ... fatal, with a mortality rate of 10.9 deaths per ... cancer patients has highlighted a significant need for new ... met by the current market. A highly active ... varying molecule types and mechanisms of action, which provides ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... attained very promising results on their initial investigations of a ... mass spectrometry of a single drop of blood serum, the ... of the patients tested. The results can be found online ... . "Because ovarian cancer is a disease of ...
... As much as 12 percent of the worlds human-caused greenhouse ... charcoal-like substance made from plants and other organic materials. Thats ... and materials were burned to generate energy, concludes a study ... calculations show that biochar can play a significant role in ...
... marine mosasaur Platecarpus , lived in the Cretaceous Period some ... an eel. That theory is debunked in a new paper published ... of scientists have reconceived the animal,s morphology, or body plan, based ... Los Angeles County. The paper was co-authored by ...
Cached Biology News:Initial trials on new ovarian cancer tests exhibit extremely high accuracy 2Charcoal takes some heat off global warming 2Charcoal takes some heat off global warming 3Charcoal takes some heat off global warming 4Charcoal takes some heat off global warming 5Mosasaur fossil at Natural History Museum of L.A. County re-explores 85-million-year-old sea monster 2
(Date:8/3/2015)... Aug. 3, 2015  ArroGen Group, an integrated ... Fingerprint Molecular Identification™ (FMID) technology Aug. 2-8 at ... Sacramento, Calif. ... enable law enforcement agents, district attorneys and government ... suspects. By analyzing chemical residues on ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... Nine field ... Iowa, Illinois and Indiana. Hosted by the Soil Health Partnership , the field ... lasting environmental benefits while potentially increasing farm productivity and income. , Brent Bible has ...
(Date:8/3/2015)... , Aug. 3, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. ... focused on the development of autologous cell therapies, announced today ... at the InvestMNT conference held in Minneapolis, Minnesota ... local time. Hall,s presentation will highlight RepliCel,s 18-month milestones including ... Europe , clinical data from both RCT-01 ...
(Date:7/31/2015)... ... July 31, 2015 , ... R-Biopharm is proud to announce ... gluten in foods, has been accepted by AOAC International as Official First Action ... Fermented Cereal-Based Products by R5 Competitive ELISA,” based on a specific monoclonal antibody ...
Breaking Biology Technology:ArroGen Previews New Fingerprint Molecular Identification Technology 2Soil Health Field Days Kick Off Throughout Midwest 2Soil Health Field Days Kick Off Throughout Midwest 3RepliCel Presenting at InvestMNT Investor Conference in Minneapolis 2RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2
... TGH to Enhance Clinical Skills,Development, DENVER, Nov. ... partnership with the University of South Florida (USF) ... Health hospital,partners and for local and national health ... Center is located at Tampa,General Hospital, a major ...
... 10 NeurogesX, Inc.,(Nasdaq: NGSX ), a ... management therapies, announced today that,Anthony DiTonno, President and ... Rodman & Renshaw 10th Annual Healthcare Conference in ... DiTonno and Stephen Ghiglieri,Chief Financial Officer, will also ...
... Company Registered in Switzerland, Will Move its Headquarter ... Various Issues Related to Neovascularisation, - Gene Signal is Working ... Now in Phase III Trials, - Gene Signal Will Present ... the American Academy of Ophtalmologist in Atlanta, USA, the ...
Cached Biology Technology:Medical Simulation Corporation Announces Partnership With University of South Florida 2Medical Simulation Corporation Announces Partnership With University of South Florida 3NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference 2NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference 3Gene Signal Enters Phase III Clinical Tests for the Prevention of Corneal Graft Rejection 2Gene Signal Enters Phase III Clinical Tests for the Prevention of Corneal Graft Rejection 3
Any form, any size, any number of mutageneses. ExonBio provides the best service with double sequecing to make sure the success of the mutagenesis....
Loading Buffer...
Request Info...
Request Info...
Biology Products: